AdAlta Ltd Earns Oral Presentation Slot for East to West CAR T Model

AdAlta abstract selected for oral presentation at ISCT ANZ 2026

AdAlta (ASX:1AD) has had an abstract describing its “East to West” business model selected, on the basis of a high peer-review score, for oral presentation at the International Society for Cell & Gene Therapy (ISCT) ANZ 2026 Regional Meeting in Melbourne (20–22 July 2026).

The selection represents independent, peer-reviewed recognition of the company’s differentiated, capital-efficient strategy for commercialising solid tumour CAR-T therapies. For a clinical-stage biotech, that kind of external validation carries weight among the scientists, clinicians and partners central to executing its plans.

What the recognition means for AdAlta

The abstract describes how the “East to West” business model brings promising Asian cell therapies to Western patients in a de-risked, capital efficient manner. It features AdAlta’s collaboration with Shanghai Cell Therapy Group on lead product BZDS1901, now known by AdAlta product code EW-001.

The submission also details manufacturing collaborations with Cell Therapies Pty Ltd and Oribiotech, aimed at delivering scalable, lower-cost CAR-T manufacturing across the Asia-Pacific.

CAR-T manufacturing costs have historically been a barrier to broader patient access, with conventional processes requiring 9 or more days and expensive viral vector inputs; the IRO automated platform being deployed through the Cell Therapies and Oribiotech partnership targets 30-50% cost reductions and 10-50x higher throughput versus legacy methods.

For investors, the significance is largely reputational. Selection for an oral slot raises AdAlta’s profile among the scientists, clinicians, regulators and potential partners who are central to its commercialisation strategy.

CEO Commentary

“Being chosen for an oral presentation is independent validation that our ‘East to West’ model is genuinely novel and important. Connecting Asia’s remarkable cell therapy innovation with Australia’s world-class manufacturing and regulatory ecosystem is a credible, capital-efficient way to bring groundbreaking immunotherapies to cancer patients who currently have few options. We are proud to share this story with the region’s leading scientists, clinicians and developers.” said Dr Tim Oldham, CEO and Managing Director of AdAlta.

Presentation details are as follows:

• Meeting: ISCT ANZ 2026 Regional Meeting, Melbourne Convention and Exhibition Centre

• Title: “An East-to-West business model for commercialising solid tumour CAR-T therapies”

• Presenter: Dr Tim Oldham, CEO & Managing Director

• Oral session: Monday, 20 July 2026, 8:00–9:00 am

• Poster: Monday, 20 July 2026, 6:00–8:00 pm; Tuesday, 21 July 2026, 6:00–7:00 pm

Understanding the ‘East to West’ model and CAR-T therapy

CAR-T cell therapies are living drugs manufactured from a patient’s own immune cells, engineered to find and kill cancer. They offer the potential for durable cancer control or a cure from a single treatment.

Under its “East to West” strategy, AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies. Each product is then positioned for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialisation.

The appeal for investors lies in the model’s design: capital efficient, replicable, and scalable across multiple products. The target market is substantial, with solid tumours accounting for 90% of cancers yet remaining underserved by current cellular immunotherapies.

According to company materials, the cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US$20.3 billion by 2028.

EW-001 and the clinical opportunity

EW-001, formerly BZDS1901, is described as a novel, first-in-class CAR-T cell therapy designed to treat mesothelioma, a rare but rapidly fatal cancer usually linked to asbestos exposure, with possible application in more than ten other cancers.

The table below compares reported outcomes for current mesothelioma treatments against early EW-001 data. The EW-001 figures are drawn from clinical studies in relapsed or advanced patients (second line and later) conducted in China, and are separate datasets rather than head-to-head trial results.

The company has stated these early results suggest EW-001 may offer a potential new treatment option for patients with few alternatives.

The EW-001 mesothelioma trial results reported earlier in 2026 provide the clinical foundation for these comparisons, with two patients achieving full tumour clearance and one remaining disease-free 18 months after a single dose across a ten-patient cohort of heavily pre-treated patients.

Next steps and strategic significance

Looking ahead, AdAlta continues to advance manufacturing transfer, US FDA engagement, and preparations for Australian Phase I development of EW-001 (BZDS1901).

Management has positioned the “East to West” approach as a replicable, capital-efficient model designed to create value across multiple products. Separately, the company’s first-in-class fusion protein AD-214, which targets fibrotic diseases of the lung and kidney and has completed two successful Phase I clinical studies, is available for partnering.

The recognition at ISCT ANZ 2026 places AdAlta in front of the region’s leading scientists, clinicians and potential partners, reinforcing the profile of a strategy that depends on those relationships to succeed.

Don’t Miss the Next Biotech Breakthrough on the ASX

Big News Blast delivers FREE breaking ASX healthcare and biotech news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next big announcement the moment it drops.